Abstract
The adverse inflammatory response is the key factor in the pathophysiology of both multiple sclerosis and other immunopathological disorders. It is characterized by the loss of homeostatic regulation of the immune system.
Current paradigma accenting abnormal polarisation of T cells subsets with substantial contribution of B cells is solid background for effective treatment approaches in multiple sclerosis patients. Large spectrum of drugs different in their molecular nature and mechanisms of action is available.
There are strong differencies in their ability to impair protective inflammation and the risk of immune system disturbances ultimating in the development of other immunopathologies. This risk is gradually increased with aging of multiple sclerosis patients.
It is also pronounced in those patients with other comorbidities linked to adverse inflammation such as obesity and diabetes.